Business Wire

OMA3

1.11.2022 20:46:43 CET | Business Wire | Press release

Share
The Open Metaverse Alliance (OMA3) Launches at Web Summit in Lisbon

Today, OMA3™ (Open Metaverse Alliance), an association based in Zug, Switzerland, is announcing open membership to its first working groups at Web Summit, Europe’s largest tech conference.

Initial working group participants include some of the biggest and most innovative names in the space such as Animoca Brands, Alien Worlds, Dapper Labs, MetaMetaverse, SPACE Metaverse, SuperWorld, The Sandbox, Upland, Voxels, Unstoppable Domains, and Wivity (the agent to the consortium).

One of the core values of the metaverse is celebrating the decentralization of not only assets but power and influence as well. OMA3 achieves this by ensuring virtual land, identities, digital assets, ideas, and services are highly interoperable between platforms and transparent to all communities. OMA3’s Portaling and Mapping Working Group will create standards that allow users to port between virtual worlds. The Asset Transfer Working Group will standardize infrastructure for moving digital assets between virtual worlds. The Legal Working Group will examine the protection and fair use of intellectual property in Web3 applications and monitor developments in the regulatory environment. Companies wishing to participate in these working groups are invited to join OMA3 as a Creator Member on its website- OMA3.org.

As the metaverse continues to grow and develop at a rapid pace, the association will continue to nurture an open, interoperable metaverse by launching more working groups in areas such as participant safety, privacy, and cybersecurity.

Dirk Lueth, Co-founder & Co-CEO, Upland, Founding Member and Chairperson of OMA3 said, “The vision of OMA3 is to move from a platform-controlled Web2-world to a user-centric Web3-Metaverse. To achieve this, we have formed an alliance of Web3 companies who want to solve interoperability challenges for the metaverse, and we aim to leverage the alliance’s knowledge and web3 native insight to help propose and set the operating standard for interoperability in the metaverse.”

Batis Samadian, Founder & CEO, SPACE, Founding Member, and Vice Chair of OMA3 said, “Decentralization and interoperability require coordination to be successful. We are pleased that the OMA3 idea we hatched in the early days has resonated so well with the industry.”

All members of OMA3 have a shared belief in an Open Metaverse without restraining walls, where individual platforms are interconnected and fully interoperable so users can move their digital assets freely across worlds. To realize this goal, OMA3 has been formed and looks forward to members joining its mission.

Sébastien Borget, Co-Founder and COO of The Sandbox and Founding Member of OMA3 said, “within the Open Metaverse, digital assets freely move across OMA3 virtual worlds, enjoying increased security and better asset tracking across worlds. With these shared standards, users will be able to take digital items that they own from one metaverse to another, enabling a universe of interconnected virtual worlds that prioritizes user experience and ownership over platform dominance and censorship.”

Saro McKenna, CEO of Alien Worlds and Founding Member of OMA3 said, “OMA3’s vision centers on striving to create an open metaverse that is also community run, decentralized and indexable, where users will be able to own and use their digital assets (e.g. NFTs), identity and reputation in a frictionless way across multiple platforms. In OMA3’s vision users are in control of their assets, not platform owners, while ideas and services are based on the foundation of decentralization and interoperability to optimize for individual freedom, social, economic, and other sustainable outcomes.”

OMA3 is committed to ensuring data is permissionless, interoperable, and fully user-controlled, with DAO governance-centered principles of inclusiveness, transparency, and decentralization. As such, OMA3 is open to all Web3 metaverse builders; companies can join as creators or community members. To learn more about participation, please visit www.oma3.org.

About OMA3

OMA3, (Open Metaverse Alliance) is a consortium comprised of leading metaverse native companies The Sandbox, Animoca Brands, Alien Worlds, Dapper Labs, Decentraland, MetaMetaverse, Space, SuperWorld, Upland, Voxels, Unstoppable Domains, and Wivity. OMA3 seeks to ensure virtual land, digital assets, ideas, and services are highly interoperable between platforms and transparent to all communities.

Twitter: twitter.com/oma3dao

Website: www.oma3.org/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005819/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye